Development status

Malignant melanoma

Melanoma is a malignant transformation of pigment-producing cells called melanocytes in the epidermis, and is considered to be a highly malignant form of skin cancer with a high metastatic rate.

PAI-1 inhibitor was shown to enhance the therapeutic effect of anti-PD-1 antibody on melanoma in a mouse tumor-bearing model transplanted with melanoma cell lines, indicating that PAI-1 inhibitor improves the immune environment in the tumor to facilitate the action of anti-PD-1 antibody.

Phase II Study

Since July 2021, an investigator-initiated clinical trial (Phase II study) has been conducted to confirm the efficacy and safety of PAI-1 inhibitor in combination with nivolumab in collaboration with six universities that have established the Japan Skin Cancer Network (JSCaN), a non-profit organization, to improve treatment outcomes for melanoma. As of March 2022, patient enrollment is progressing well.